joint emea efpia information session
play

Joint EMEA/ EFPIA Information Session 11 September 2006 in London - PowerPoint PPT Presentation

Sep 12, 2023 •43 likes •83 views

Joint EMEA/ EFPIA Information Session 11 September 2006 in London Ann Robins Legal Affairs Manager 1 The pharmaceutical industry is a major asset to the EU economy It employs almost 615,000 people in total, of whom 103,000 are engaged

  1. Joint EMEA/ EFPIA Information Session 11 September 2006 in London Ann Robins Legal Affairs Manager 1

  2. The pharmaceutical industry is a major asset to the EU economy • It employs almost 615,000 people in total, of whom 103,000 are engaged in R&D activities • It is the leading high-technology sector in terms of trade surplus in Europe, amounting to almost €33bn in 2004 • Its contribution to trade is growing, accounting for >5% of total EU manufacturing exports in 2004, compared with 2% in 1990 2

  3. EFPIA • The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the research-based pharmaceutical industry operating in Europe. • Founded in 1978, its members comprise: –30 national pharmaceutical associations –44 pharmaceutical companies Through its membership, EFPIA represents the common views of about 2,100 large, medium and small companies including the entire European research-based pharmaceutical sector. • Two specialised groups within EFPIA: –EFPIA/EVM - European Vaccine’s Manufacturers (8) –EFPIA/EBE – European Biopharmaceutical Enterprises (38) 3

  4. EFPIA Mission EFPIA mission is to promote pharmaceutical research and development and the best conditions for companies to bring to market medicines that improve human health and the quality of life around the world 4

Recommend

EMEA Performance Indicators Pre-Authorisation Bo Aronsson EMEA EMEA-EFPIA Info Day 2009 1

EMEA Performance Indicators Pre-Authorisation Bo Aronsson EMEA EMEA-EFPIA Info Day 2009 1

EMEA Performance Indicators Pre-Authorisation Bo Aronsson EMEA EMEA-EFPIA Info Day 2009 1 Contents Analysis Period EMEA questionnaires Results Summary Work in progress (Predictors of outcome) Conclusions 2

269 views • 26 slides
EMEA EFPIA Workshop 19Dec08 Integrating PGx Early into Drug Development: PK as a working

EMEA EFPIA Workshop 19Dec08 Integrating PGx Early into Drug Development: PK as a working

EMEA EFPIA Workshop 19Dec08 Integrating PGx Early into Drug Development: PK as a working example 1 EMEA-EFPIA Workshop on PGx 2008 - CASE 3 EMEA/EFPIA PGx in PK Workshop Case 3: PGx Data Submission to Biomarker Scientific Advice Task: What

569 views • 25 slides
EMEA Performance Indicators Extensions of Indications Manuel Haas EMEA-EFPIA Info Day 2009 1

EMEA Performance Indicators Extensions of Indications Manuel Haas EMEA-EFPIA Info Day 2009 1

EMEA Performance Indicators Extensions of Indications Manuel Haas EMEA-EFPIA Info Day 2009 1 Contents Methods Procedures Overview Requests for supplementary information & Major objections Review times

482 views • 15 slides
Joint EMEA (NRG)/EFPIA Workshop 11 September 2006 in London Guideline on acceptability of

Joint EMEA (NRG)/EFPIA Workshop 11 September 2006 in London Guideline on acceptability of

Joint EMEA (NRG)/EFPIA Workshop 11 September 2006 in London Guideline on acceptability of invented names Hanne Brokopp (MSD) 2 Guideline Guideline states The use of short qualifiers which do not carry established and relevant meaning in

341 views • 7 slides
EMEA EFPIA Workshop 19Dec08 Integrating Pgx Early into Drug Development: PK as a working

EMEA EFPIA Workshop 19Dec08 Integrating Pgx Early into Drug Development: PK as a working

EMEA EFPIA Workshop 19Dec08 Integrating Pgx Early into Drug Development: PK as a working example 1 EMEA-EFPIA Workshop on PGx 19 Dec 2008 - CASE 4 Overview: 4 Sessions over a DAY Workshop Goal: Collaborative efforts on future paper or

358 views • 22 slides
EMA EFPIA workshop EMA EFPIA workshop Break- -out session no. 4 out session no. 4 Break

EMA EFPIA workshop EMA EFPIA workshop Break- -out session no. 4 out session no. 4 Break

EMA EFPIA workshop EMA EFPIA workshop Break- -out session no. 4 out session no. 4 Break Longitudinal model-based test as primary analysis in phase III B. Bieth*, D. Renard*, I. Demin*, B. Hamrn*, G. Heimann*, Sigrid Balser** *

402 views • 15 slides
EFPIA POSITION PAPER EFPIA POSITION PAPER THE EFPIA SURROGATE THE EFPIA SURROGATE ENDPOINT

EFPIA POSITION PAPER EFPIA POSITION PAPER THE EFPIA SURROGATE THE EFPIA SURROGATE ENDPOINT

EFPIA POSITION PAPER EFPIA POSITION PAPER THE EFPIA SURROGATE THE EFPIA SURROGATE ENDPOINT INITIATIVE ENDPOINT INITIATIVE EMEA/EFPIA Workshop on Biomarkers EMEA/EFPIA Workshop on Biomarkers London 15 December 2006 15 December 2006

586 views • 19 slides
EMA EFPIA workshop EMA EFPIA workshop Breakout Session 3 Breakout Session 3 Evidence Synthesis

EMA EFPIA workshop EMA EFPIA workshop Breakout Session 3 Breakout Session 3 Evidence Synthesis

EMA EFPIA workshop EMA EFPIA workshop Breakout Session 3 Breakout Session 3 Evidence Synthesis in Drug Development for Special Populations, Ethnic Groups and Rare Diseases Oscar Della Pasqua GlaxoSmithKline LEADING STATEMENTS LEADING

465 views • 11 slides
Application of PGx in PK at FDA: Experience and Expectations EMEA-EFPIA Workshop Integrating PGx

Application of PGx in PK at FDA: Experience and Expectations EMEA-EFPIA Workshop Integrating PGx

Application of PGx in PK at FDA: Experience and Expectations EMEA-EFPIA Workshop Integrating PGx into Early Drug Development London UK 19 December 2008 Lawrence J. Lesko, Ph.D., F.C.P. Office of Clinical Pharmacology Center for Drug

116 views • 10 slides
EMA EFPIA workshop EMA EFPIA workshop Breakout Session 2 Breakout Session 2 Assessing the

EMA EFPIA workshop EMA EFPIA workshop Breakout Session 2 Breakout Session 2 Assessing the

EMA EFPIA workshop EMA EFPIA workshop Breakout Session 2 Breakout Session 2 Assessing the Probability of Drug-Induced QTc-Interval Prolongation During Early Clinical Drug Development Oscar Della Pasqua GSK Background Background Drugs that

511 views • 19 slides
EMA EFPIA workshop EMA EFPIA workshop Break- -out session no. out session no. 2 2 Break

EMA EFPIA workshop EMA EFPIA workshop Break- -out session no. out session no. 2 2 Break

EMA EFPIA workshop EMA EFPIA workshop Break- -out session no. out session no. 2 2 Break Case Study Title: Design of a model based Case Study Title: dose-finding study in diabetes Marie Sandstrm, Global Director Clinical Pharmacometrics,

605 views • 14 slides
EMEA/EFPIA WORKSHOP ON BIOMARKERS CARDIOVASCULAR BIOMARKERS A regulatory perspective Gonzalo

EMEA/EFPIA WORKSHOP ON BIOMARKERS CARDIOVASCULAR BIOMARKERS A regulatory perspective Gonzalo

EMEA/EFPIA WORKSHOP ON BIOMARKERS CARDIOVASCULAR BIOMARKERS A regulatory perspective Gonzalo Calvo Spanish Agency on Medicines and Healthcare products Biomarker A characteristic that is objectively measured and evaluated as an indicator of

467 views • 14 slides
EMEA MEETING WITH INTERESTED PARTIES On the Review Process on Names for Medicinal Products 11 th

EMEA MEETING WITH INTERESTED PARTIES On the Review Process on Names for Medicinal Products 11 th

EMEA MEETING WITH INTERESTED PARTIES On the Review Process on Names for Medicinal Products 11 th September 2006 in London Presentation by EFPIA Ann Robins (EFPIA) - Catherine Boudot (Laboratoires Servier) 1/22 1. OBJECTIVES OF THE DAY

257 views • 22 slides
The 2007 trends: EMEA analysis EMEA analysis The 2007 trends: Francesco Pignatti, MD Safety and

The 2007 trends: EMEA analysis EMEA analysis The 2007 trends: Francesco Pignatti, MD Safety and

EMEA- -EFPIA INFO DAY EFPIA INFO DAY EMEA 5 February 2007 5 February 2007 Analysis of Performance Indicators for Analysis of Performance Indicators for Initial Applications/Full Applications Initial Applications/Full Applications The 2007

381 views • 22 slides
EMA EFPIA workshop EMA EFPIA workshop Break- -out session no. 3 out session no. 3 Break

EMA EFPIA workshop EMA EFPIA workshop Break- -out session no. 3 out session no. 3 Break

EMA EFPIA workshop EMA EFPIA workshop Break- -out session no. 3 out session no. 3 Break Pharmacokinetic- -pharmacodynamic assessment of pharmacodynamic assessment of Pharmacokinetic topiramate dosing regimens for children with

421 views • 12 slides
Case 3: PGx Data Submission to Biomarker Scientific Advice Task: What does the team do next? 1

Case 3: PGx Data Submission to Biomarker Scientific Advice Task: What does the team do next? 1

EMEA/EFPIA PGx in PK Workshop Case 3: PGx Data Submission to Biomarker Scientific Advice Task: What does the team do next? 1 EMEA-EFPIA Workshop on PGx 2008 - CASE 3 Scenario 1 Hypothesis driven Two Phase 1 studies available with PGx data

705 views • 12 slides
EMA EFPIA workshop EMA EFPIA workshop EMA EFPIA workshop EMA EFPIA workshop Break Break- -out

EMA EFPIA workshop EMA EFPIA workshop EMA EFPIA workshop EMA EFPIA workshop Break Break- -out

EMA EFPIA workshop EMA EFPIA workshop EMA EFPIA workshop EMA EFPIA workshop Break Break- -out session no. 2 out session no. 2 Case Study Title: Case Study Title: M&S for dose adjustment in M&S for dose adjustment in renally

363 views • 25 slides
Heterogeneity Over Time in Clinical Trials Keaven M. Anderson, Jason B. Clark, Kenneth S. Liu

Heterogeneity Over Time in Clinical Trials Keaven M. Anderson, Jason B. Clark, Kenneth S. Liu

Heterogeneity Over Time in Clinical Trials Keaven M. Anderson, Jason B. Clark, Kenneth S. Liu Merck Research Laboratories EMEA / EFPIA Workshop on Adaptive Designs December 14, 2007 EMEA / EFPIA Workshop on Adaptive Designs

197 views • 17 slides
EMA EFPIA workshop EMA EFPIA workshop Break- -out session no. out session no. 3 3 Break

EMA EFPIA workshop EMA EFPIA workshop Break- -out session no. out session no. 3 3 Break

EMA EFPIA workshop EMA EFPIA workshop Break- -out session no. out session no. 3 3 Break Case Study Title: Evaluation of fixed dose Evaluation of fixed dose Case Study Title: combinations in paediatric indications - - Use of

399 views • 23 slides
EMA EFPIA workshop EMA EFPIA workshop Break- -out session no. out session no. 2 2 Break

EMA EFPIA workshop EMA EFPIA workshop Break- -out session no. out session no. 2 2 Break

EMA EFPIA workshop EMA EFPIA workshop Break- -out session no. out session no. 2 2 Break Case Study Title: Dose Finding under Model Dose Finding under Model Case Study Title: Uncertainty A case study based on a multi-

165 views • 13 slides
EMA EFPIA workshop EMA EFPIA workshop Break- -out session no. 4 out session no. 4 Break

EMA EFPIA workshop EMA EFPIA workshop Break- -out session no. 4 out session no. 4 Break

EMA EFPIA workshop EMA EFPIA workshop Break- -out session no. 4 out session no. 4 Break Modelling to guide Regulatory Modelling to guide Regulatory Guidelines and decision making during Guidelines and decision making during development

772 views • 11 slides
EMA- -EFPIA M&S Workshop EFPIA M&S Workshop - - Session 3 EMA Session 3 M&S

EMA- -EFPIA M&S Workshop EFPIA M&S Workshop - - Session 3 EMA Session 3 M&S

EMA- -EFPIA M&S Workshop EFPIA M&S Workshop - - Session 3 EMA Session 3 M&S examples that failed or succeeded to M&S examples that failed or succeeded to meet regulators expectations meet regulators expectations

365 views • 18 slides
1 3ISP Industrial specialised distributor partners for industry active in the EMEA Region

1 3ISP Industrial specialised distributor partners for industry active in the EMEA Region

3 ISP INDUSTRIAL SPECIALISED PARTNERS EMEA Region 3 ISP- INDUSTRIAL SPECIALISED PARTNERS-EMEA Region 3 ISP is a joint venture that unites three leading distributors in the EMEA area, specialising in value-added products and services for

490 views • 11 slides
Integrated application of a QbD Development Approach across Chemical and Formulation

Integrated application of a QbD Development Approach across Chemical and Formulation

Integrated application of a QbD Development Approach across Chemical and Formulation Manufacturing Process Gert Thurau, Merck Sharp & Dohme Evdokia Korakianiti, EMEA 29/09/2009 EMEA/Efpia QbD Application Workshop - London Case Study

140 views • 10 slides

More recommend